Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia

7Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Setting-up a high quality, compliant and efficient pharmacovigilance (PV) system in multi-country clinical trials can be more challenging for academic sponsors than for companies. To ensure the safety of all participants in academic studies and that the PV system fulfils all regulations, we set up a centralized PV system that allows sponsors to delegate work on PV. This initiative was put in practice by our Inserm-ANRS MIE PV department in two distinct multinational European consortia with 19 participating countries: conect4children (c4c) for paediatrics research and EU-Response for Covid-19 platform trials. The centralized PV system consists of some key procedures to harmonize the complex safety processes, creation of a local safety officer (LSO) network and centralization of all safety activities. The key procedures described the safety management plan for each trial and how tasks were shared and delegated between all stakeholders. Processing of serious adverse events (SAEs) in a unique database guaranteed the full control of the safety data and continuous evaluation of the risk–benefit ratio. The LSO network participated in efficient regulatory compliance across multiple countries. In total, there were 1312 SAEs in EU-Response and 83 SAEs in c4c in the four trials. We present here the lessons learnt from our experience in four clinical trials. We managed heterogeneous European local requirements and implemented efficient communication with all trial teams. Our approach builds capacity for PV that can be used by multiple academic sponsors.

References Powered by Scopus

Implementing a centralised pharmacovigilance service in a non-commercial setting in the United Kingdom

5Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Advocating for drug development in newborn infants

2Citations
N/AReaders
Get full text

Development and performance of the c4c national clinical trial networks for optimizing pediatric trial facilitation

1Citations
N/AReaders
Get full text

“Common sense is hard work” but benefits from persistent collaboration: Lessons learnt from the development of The Collaborative Network for European Clinical Trials for Children (c4c) to support the conduct of paediatric clinical trials of medicines

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Terzić, V., Levoyer, L., Figarella, M., Bigagli, E., Mercier, N., De Gastines, L., … Warris, A. (2023, April 1). Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia. British Journal of Clinical Pharmacology. John Wiley and Sons Inc. https://doi.org/10.1111/bcp.15669

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

50%

Professor / Associate Prof. 2

33%

Researcher 1

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

43%

Neuroscience 2

29%

Pharmacology, Toxicology and Pharmaceut... 1

14%

Social Sciences 1

14%

Save time finding and organizing research with Mendeley

Sign up for free